Radiographic patterns of progression in patients with EGFR-mutant NSCLC undergoing EGFR TKI therapy.

被引：0
|
作者：
Brenner, Nicole [1 ]
Bastos, Bruno R. [1 ]
机构：
[1] Cleveland Clin Florida, Weston, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19108
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Immunomodulatory Effects of Afatinib and Pembrolizumab in EGFR-Mutant NSCLC with Progression on Prior EGFR-TKI
    Riess, J.
    Kelly, K.
    Schalper, K.
    Shimoda, M.
    Lim, S.
    Monjazeb, A.
    Danenberg, K.
    Moore, E.
    Beckett, L.
    Mack, P.
    Maverakis, E.
    Gandara, D.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S528 - S528
  • [2] Predicting duration of response to EGFR TKI among EGFR-mutant NSCLC patients.
    Sakr, Lama
    Kasymjanova, Goulnar
    Small, David I.
    Cohen, Victor
    Galvis, Luisa
    Pepe, Carmela
    Agulnik, Jason Scott
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
    Remon, J.
    Steuer, C. E.
    Ramalingam, S. S.
    Felip, E.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : I20 - I27
  • [4] A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy
    Song, Jiangdian
    Shi, Jingyun
    Dong, Di
    Fang, Mengjie
    Zhong, Wenzhao
    Wang, Kun
    Wu, Ning
    Huang, Yanqi
    Liu, Zhenyu
    Cheng, Yue
    Gan, Yuncui
    Zhou, Yongzhao
    Zhou, Ping
    Chen, Bojiang
    Liang, Changhong
    Liu, Zaiyi
    Li, Weimin
    Tian, Jie
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (15) : 3583 - 3592
  • [5] Tepotinib Plus an EGFR TKI in Patients with EGFR-mutant NSCLC and Resistance to EGFR TKIs Due to MET Amplification (METamp)
    Liam, C. K.
    Ahmad, A. Rozila
    Hsia, T.
    Li, J. Y.
    Le, X.
    Heymach, J.
    Yang, J. C.
    Soo, R.
    Zhang, Y.
    Kim, S.
    Shin, S. W.
    Johne, A.
    Karachaliou, N.
    Bruns, R.
    Ellers-Lenz, B.
    Wu, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1118 - S1119
  • [6] EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models
    Laurila, Niina
    Koivunen, Jussi P.
    [J]. MEDICAL ONCOLOGY, 2015, 32 (07)
  • [7] EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models
    Niina Laurila
    Jussi P. Koivunen
    [J]. Medical Oncology, 2015, 32
  • [8] Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors
    Nishino, Mizuki
    Cardarella, Stephanie
    Dahlberg, Suzanne E.
    Jackman, David M.
    Ramaiya, Nikhil H.
    Hatabu, Hiroto
    Rabin, Michael S.
    Jaenne, Pasi A.
    Johnson, Bruce E.
    [J]. LUNG CANCER, 2013, 79 (03) : 283 - 288
  • [9] Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors
    Nishino, Mizuki
    Heon, Stephanie
    Dahlberg, Suzanne Eleanor
    Jackman, David Michael
    Ramaiya, Nikhil H.
    Hatabu, Hiroto
    Rabin, Michael S.
    Janne, Pasi Antero
    Johnson, Bruce E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Erlotinib as adjuvant therapy in EGFR-mutant NSCLC
    Jassem, Jacek
    [J]. LANCET RESPIRATORY MEDICINE, 2018, 6 (11): : 808 - 810
12345